SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Krikor who wrote (210)2/24/2003 4:36:32 PM
From: farkarooski  Read Replies (2) of 250
 
2:28PM Vaxgen: Punk Ziegel comments on trial results (VXGN) 5.91 -7.11: --Update-- To give readers an idea of analysts' take on the co's AIDSVAX trial, we refer to a Punk Ziegel note out this morning. According to firm, while the trial failed to protect the study group as a whole from infection with HIV, the vaccine was effective in two prospectively defined subgroups: The vaccine was 78% effective in blacks and 67% effective in a slightly larger group of non-white volunteers. Firm thinks the trial results were clearly a success scientifically and from the public health perspective, as AIDSVAX is the first vaccine shown to prevent HIV in any population. Based on the preliminary data outlined in this morning's press release and on firm's preliminary calculations of the U.S. market for a vaccine effective only in blacks, Punk Ziegel believes that VaxGen's shares are currently worth between $35-$45 a share.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News